ANVISA expanded its regulatory initiative focused on reducing evaluation queues for biological products. The project aims to improve review timelines, optimize resource allocation, and enhance efficiency in the assessment of biologics, supporting faster regulatory decision-making and improved market access.
Select Mandate HA
Select Mandate Function